Phase I Toxicity Trial of Doxorubicin-Cisplatin Followed by Whole Abdominal Irradiation for Advanced Endometrial Carcinoma
- Determine the feasibility of doxorubicin and cisplatin followed by whole abdominal
radiotherapy in patients with stage III or IV endometrial cancer.
- Determine the acute and chronic toxic effects, in particular, severe and
life-threatening gastrointestinal, hepatic, and hematologic toxic effects, of this
regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive doxorubicin IV and cisplatin IV on day 1. Treatment repeats every 3 weeks
for 3 courses. Patients then undergo whole abdominal radiotherapy 5 days a week for 4-6
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
PROJECTED ACCRUAL: A total of 21-53 patients will be accrued for this study within 3.5
Masking: Open Label, Primary Purpose: Treatment
Jeffrey M. Fowler, MD
Ohio State University Comprehensive Cancer Center
United States: Federal Government
|Fred Hutchinson Cancer Research Center||Seattle, Washington 98109|
|University of Chicago Cancer Research Center||Chicago, Illinois 60637|
|Indiana University Cancer Center||Indianapolis, Indiana 46202-5265|
|Case Comprehensive Cancer Center||Cleveland, Ohio 44106-5065|
|Lake/University Ireland Cancer Center||Mentor, Ohio 44060|
|University Cancer Center at University of Washington Medical Center||Seattle, Washington 98195|